Cambridge, Massachusetts — January 14, 2020 — Ideaship, a patent leveraged venture capital firm that provides patent development support to early-stage startups, announced it has invested in Imaginostics. The investment will support Imaginostics’ mission to innovate non-invasive diagnostic solutions that will provide new insight into health and disease.
“Imaginostic’s QUTE-CE MRI platform represents a major break-through in medical diagnostics. It provides unparalleled, quantitative vascular imaging, which will significantly transform biomarker detection and change the way we are able to see and understand aging and complex diseases. It will provide unique insights into the vasculature, such as how microvasculature is structured, how blood vessels dilate and mapping any blood-brain barrier leakage,” said Robert Bell, Ideaship Venture Partner.
“Imaginostics has partnered with Ideaship to ensure the success of our early products and services via a strong IP portfolio. Our vascular imaging technology is ready to help millions of chronic kidney disease patients by empowering clinicians with safer tools for vascular imaging. As a startup, we’ve been flying under the radar. However, large markets draw the attention of big companies. Our go-to-market products are important, and we have a pipeline of innovative diagnostic solutions to reach neurodegenerative disease, to help fight cancer, to expand access to high quality diagnostic imaging to broader patient populations and more. Ultimately, it’s not about our success, but about the difference we can make in people’s lives if we are successful,” said Codi Gharagouzloo, CEO of Imaginostics.
Imaginostics is a health technology and longevity startup that is pushing the frontiers of medical imaging diagnostics for precision medicine and to expand access to high quality imaging to broader patient populations. Imaginostics’ vision is to detect diseases years before the apparition of symptom onset and to help prevent them. Its breakthrough MRI, unique physics-based software and quantitative vascular imaging biomarkers for use with existing MRI machines provide clinicians and scientists new diagnostic insights for the early detection and enhanced characterization of complex diseases, that will ultimately revolutionize the aging paradigm and help improve quality of life for a maturing population.
Ideaship provides patent development capital for early-stage ventures.
Ideaship is a collaboration between Global Technology Transfer Group (GTT Group) and Panasonic Intellectual Property Corporation of America (PIPCA). Ideaship combines GTT Group’s patent experience with PIPCA’s leading patent department expertise, achieving enterprise value premiums.